接受新辅助化疗的三阴性乳腺癌患者病理完全缓解与总生存的种族/民族差异
非西班牙裔黑人患者达到pCR的几率低于非西班牙裔白人(OR 0.89),西班牙裔患者高于非西班牙裔白人(OR 1.19);调整后西班牙裔(HR 0.76)和非西班牙裔亚裔(HR 0.64)与OS相关。
要点
- 非西班牙裔黑人患者达到pCR的几率低于非西班牙裔白人(OR 0.89,95%CI 0.83-0.95,P=.001)
- 西班牙裔患者达到pCR的几率高于非西班牙裔白人(OR 1.19,95%CI 1.08-1.31,P=.001)
- pCR对OS的影响不因种族/民族而异(交互作用P=.10)
核心结论
- 三阴性乳腺癌患者达到pCR的几率和OS似乎与种族/民族相关;需要更多研究来理解种族/民族与pCR率和OS的相关性是否与社会经济因素或生物学变量或两者有关。
研究设计与样本
- 基于美国国家癌症数据库(2010-2019年)的队列研究,纳入18岁及以上I-III期接受新辅助化疗后手术的三阴性乳腺癌女性,排除无种族/民族或病理数据的患者。
主要发现
- 总体pCR率为29.8%;非西班牙裔白人30.5%,非西班牙裔黑人27%,西班牙裔32.6%,非西班牙裔亚裔28.8%,非西班牙裔其他29.8%。
- 未调整OS在达到pCR者中显著高于有残留病变者(5年OS 0.917 [95%CI 0.911-0.923] vs 0.667 [95%CI 0.661-0.673],log-rank P<.001),调整人口学和肿瘤因素后该关联持续存在。
- pCR对OS的影响不因种族/民族而异(交互作用P=.10)。
- 非西班牙裔黑人患者达到pCR的几率低于非西班牙裔白人(OR 0.89 [95%CI 0.83-0.95],P=.001),西班牙裔患者高于非西班牙裔白人(OR 1.19 [95%CI 1.08-1.31],P=.001)。
- 调整患者和疾病因素(包括达到pCR)后,西班牙裔(HR 0.76 [95%CI 0.69-0.85],P<.001)和非西班牙裔亚裔(HR 0.64 [95%CI 0.55-0.75],P<.001)仍与OS相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Black women have higher rates of death from triple-negative breast cancer (TNBC) than White women. We hypothesized that pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) and overall survival (OS) may vary by race/ethnicity in patients with TNBC. METHODS: We identified women 18 years and older with stage I-III TNBC who received NAC followed by surgery from the National Cancer Database (2010-2019). We excluded patients without race/ethnicity or pathology data. Primary outcomes were pCR rates and OS on the basis of race/ethnicity. RESULTS: Forty thousand eight hundred ninety women with TNBC met inclusion criteria (median age [IQR], 53 [44-61] years): 26,150 Non-Hispanic White (64%, NHW), 9,672 Non-Hispanic Black (23.7%, NHB), 3,267 Hispanic (8%), 1,368 Non-Hispanic Asian (3.3%, NHA), and 433 Non-Hispanic Other (1.1%, NHO) patients. Overall, 29.8% demonstrated pCR (NHW: 30.5%, NHB: 27%, Hispanic: 32.6%, NHA: 28.8%, NHO: 29.8%). Unadjusted OS was significantly higher for those with pCR compared with those with residual disease (5-year OS, 0.917 [95% CI, 0.911 to 0.923] v 0.667 [95% CI, 0.661 to 0.673], log-rank P < .001), and this association persisted after adjustment for demographic and tumor factors. The effect of achieving pCR on OS did not differ by race/ethnicity (interaction P = .10). However, NHB patients were less likely (odds ratio [OR], 0.89 [95% CI, 0.83 to 0.95], P = .001) and Hispanic patients were more likely (OR, 1.19 [95% CI, 1.08 to 1.31], P = .001) to achieve pCR than NHW patients. After adjustment for patient and disease factors, including achievement of pCR, Hispanic (hazard ratio [HR], 0.76 [95% CI, 0.69 to 0.85], P < .001) and NHA (HR, 0.64 [95% CI, 0.55 to 0.75], P < .001) race/ethnicity remained associated with OS. CONCLUSION: Odds of achieving pCR and OS in patients with TNBC appear to be associated with race/ethnicity. Additional research is necessary to understand how race/ethnicity is associated with rates of pCR and OS, whether related to socioeconomic factors or biologic variables, or both.
引用
- Woriax HE, Thomas SM, Plichta JK, et al. Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy. J Clin Oncol. 2024. PMID: 38394476. doi:10.1200/JCO.23.01199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。